Prochlorperazine vs Metoclopramide
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00364806|
Recruitment Status : Completed
First Posted : August 16, 2006
Last Update Posted : April 17, 2018
|Condition or disease||Intervention/treatment||Phase|
|Migraine||Drug: Prochlorperazine Drug: Metoclopramide||Phase 4|
One-third of the five million headache patients who present to US Emergency Departments (ED) annually have a migraine headache. The anti-emetic dopamine receptor antagonists have proven efficacy for migraines, are at least as well-tolerated as triptans, and enjoy wide-spread use in North American EDs. However, it is not yet clear which medication within this class and which dosage is optimal. Therefore, we propose a randomized clinical trial to compare the efficacy and tolerability of two standard medications for migraine.
Specific Aim: To compare the efficacy of metoclopramide versus prochlorperazine for the emergency department treatment of migraine headaches. Both of these medications will be combined with diphenhydramine to prevent extra-pyramidal side effects.
Patients will be enrolled as participants if they present to one of the participating EDs and consent to participate. Medications will be administered as an intravenous drip over 15 minutes. Rescue medication will be administered, if needed, after one hour. A follow-up phone call will be conducted 24 hours after the ED visit.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||76 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Prochlorperazine Verus Metoclopramide for the Treatment of Acute Migraine in the Emergency Department Setting|
|Study Start Date :||August 2006|
|Actual Primary Completion Date :||March 2007|
|Actual Study Completion Date :||March 2007|
- One hour pain scores
- One hour, two hour and 24 hour pain, functional disability scores, and side effect profiles.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00364806
|United States, New York|
|Montefiore Medical Center|
|Bronx, New York, United States, 10467|
|Principal Investigator:||Benjamin W Friedman, MD, MS||Albert Einstein College of Medicine|